GlobeNewsWire · 2 Oct 2026positive
Autonomix Medical announced it has strengthened its patent protection for its platform technology, expanding coverage for catheter-based technologies that enable transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall.
Why it matters — Expanded patent protection helps safeguard Autonomix's core platform technology and its intellectual property position for its catheter-based precision access and treatment delivery systems.
GlobeNewsWire · 30 Sept 2026positive
Autonomix reported positive FDA pre-submission feedback supporting a Class II 510(k) strategy for its standalone sensing platform, leveraging substantial equivalence to a previously cleared device. This positions the company for potential initial U.S. clearance in approximately 15 months.
Why it matters — FDA feedback validating a 510(k) pathway could support a more streamlined route toward initial U.S. clearance of Autonomix's sensing platform, a key commercial milestone for the company.
GlobeNewsWire · 24 Sept 2026positive
Autonomix Medical announced that it has obtained a European patent that strengthens protection for its proprietary autonomic nervous system assessment technologies, further expanding the company's international intellectual property portfolio and supporting its precision neuromodulation platform.
Why it matters — AMIX watchers would care because this expands the company's global intellectual property footprint and bolsters protection around the technology underpinning its precision neuromodulation platform.
GlobeNewsWire · 16 Sept 2026positive
Autonomix Medical, Inc. announced the appointment of Sandra Cohen Kalter, former Chief Regulatory Counsel at Medtronic, to its Board of Directors. Kalter brings more than four decades of MedTech leadership, FDA regulatory, and strategic transaction experience, including work supporting renal denervation and other category-defining technologies.
Why it matters — AMIX watchers would care because adding a veteran regulatory and MedTech leader with deep FDA experience could strengthen the company's regulatory and strategic capabilities for its product development efforts.
GlobeNewsWire · 1 Sept 2026positive
Autonomix Medical announced that two scientific abstracts have been accepted for poster presentation at the CIRSE 2026 Annual Congress, taking place September 5-9, 2026, in Copenhagen, Denmark. The abstracts highlight the potential of Autonomix's transvascular technology in pain management and nervous system mapping.
Why it matters — The acceptance of the abstracts for a major European radiological congress provides third-party validation and increased visibility for Autonomix's transvascular technology across pain management and nervous system mapping.
